Advertisement

GeneLink Settles

Another personal genomics company faces government pressure—this time from the Federal Trade Commission.

By | January 14, 2014

FLICKR, BRADLEY STEMKEJust a month after personal genomics company 23andMe announced that it would stop offering health interpretations of genetic data amidst pressure from the U.S. Food and Drug Administration, another personal genomics company is under government fire. The Federal Trade Commission (FTC) announced in a press release dated January 7 that GeneLink Biosciences, Inc., and its former subsidiary, Foru International Corp., agreed “to settle Federal Trade Commission charges of deceptive advertising for claims that their personalized nutritional supplements treat diabetes, heart disease, arthritis, insomnia, and other ailments.”

Both companies marketed supplements and skincare products allegedly customized to customers’ genomes that cost at least $100 a month. The FTC also took issue with lax security regarding customers’ personal information—including Social Security numbers and genetic data. “It doesn’t matter whether the claims deal with the benefits of direct-to-consumer genetic testing or the privacy of personal information,” Jessica Rich, the director of the FTC’s Bureau of Consumer Protection, said in the statement. “It’s against the law to deceive people about your product and to make promises you don’t keep.”

Under the terms of the settlement, GeneLink and Foru are prohibited from marketing their products as treatments for any disease, unless the claim has been validated in well-controlled studies; from making any assertions about their products improving health by modulating gene function; and from providing the means for any affiliated companies or individuals to make health claims about their products. Both companies will also be audited every other year for the next 20 in order to make sure that they adhere to information security standards.

“I think if the standard consumer, because of this type of activity, looks with somewhat of a cynical eye at such claims that’s good,” James Evans of the University of North Carolina at Chapel Hill told Scientific American. “People have to be able to trust products and claims, and when outlandish claims are exposed, in the long run that’s a good thing.”

Advertisement

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement
RayBiotech
RayBiotech

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Advertisement
Life Technologies